Mark Weir-Smith

Mark Weir-Smith is a seasoned professional in quality operations and regulatory affairs, currently serving as Senior Vice President at both NovaCina and LumaCina since January 2023, and at Bridgewest Perth Pharma since December 2022. With a robust history in the field, Mark has been a Medical Assessor for the National Association of Testing Authorities in Australia since 2002, overseeing laboratory accreditations and compliance monitoring. Previous roles include leadership positions at Western Diagnostic Pathology, Pfizer, the Australian Red Cross, and Sanofi Genzyme, where Mark specialized in quality operations and regulatory affairs. Educational credentials include a degree in Medical Science from Curtin University, additional studies at the University of Wales, and an advanced degree in Business Organisational Leadership from Harvard Business School. Mark also held a Vice President position at ISPE Australasia Affiliate and has invested significant expertise in pharmaceutical quality assurance across multiple organizations.